ArticleFolia microbiologica2026
Molecular docking, dynamics and experimental approach integrated identification of phytopharmaceuticals against methicillin-resistant Staphylococcus aureus (MRSA) infection.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is indeed a significant public health issue, affecting millions of people worldwide which can range from mild skin infections to life-threatening conditions like bloodstream infections and pneumonia. The aim of the current study is to decipher the possible mechanism of some selected natural compounds against MRSA. The natural compounds were selected based on our earlier systematic literature review. The selected compounds were screened against various targets of MRSA using molecular docking techniques. The stability of selected compounds was checked using molecular dynamics. Further, Absorption, Distribution, Metabolism and Excretion (ADME) was predicted using QikProp module. All the computational studies were conducted using the Schrodinger Maestro version 13.5.128. In-vitro assays were conducted to check the anti-bacterial effects of selected natural compounds against MRSA. Among 60 selected natural compounds, theasinensin A, xanthohumol, luteolin, oxyresveratrol, liquiritigenin and baicalin has shown the energetically favoured binding conformation in the active site of targets. Further, molecular dynamics results have shown the stable conformation of xanthohumol and theasinensin A in the active site of targets. Further, the pharmacokinetic profile of xanthohumol was found to be better among other natural compounds. The minimum inhibitory concentration (MIC) of xanthohumol was found to be 3.12 µg/mL as indicated by disk diffusion and micro broth dilution assays. Xanthohumol can be promising anti-bacterial agent against MRSA through multi modal mechanism. However, further detailed experimental studies are required to confirm its possible antibacterial mechanisms.
Indexed as
Identifiers
41540178What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.